<DOC>
	<DOCNO>NCT00931957</DOCNO>
	<brief_summary>The purpose study find Etanercept improve outcome ocular lesion Behcet 's Disease treat Methotrexate Prednisolone</brief_summary>
	<brief_title>Etanercept : Single Blind Control Study Ocular Manifestations Behcet 's Disease</brief_title>
	<detailed_description>To test randomize single blind control trial efficacy Etanercept patient posterior uveitis and/or retinal vasculitis Behcet 's disease treat Methotrexate prednisolone</detailed_description>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Uveal Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Behcet 's Disease accord International Criteria Behcet 's disease ( ICBD ) Active posterior uveitis and/or retinal vasculitis Visual acuity inferior 1/10 Snellen chart Being cytotoxic drug receive past 2 month Not able follow one year treatment regular follow ups</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Behcet 's syndrome</keyword>
	<keyword>Behcet 's Disease</keyword>
	<keyword>Ocular Lesions</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Retinal Vasculitis</keyword>
</DOC>